Hormone Peptides TRIZ Cases

Unacylated ghrelin fragments decrease ghrelin concentrations and ratios, resolving efficacy and selectivity trade-offs in metabolic disorder treatments.

N-terminal GlyMetAla tripeptide converts agonists into antagonists to inhibit food intake and growth hormone secretion.

S-alkylated hepcidin peptides modify reactive thiol groups to prevent oxidation, addressing iron overload disease side effects.

Grafting MIS binding regions onto BMP2 frameworks creates recombinant proteins that overcome chemoresistance by inducing apoptosis in ovarian cancer cells.

Choline dihydrogen phosphate preserves therapeutic proteins in liquid state, eliminating lyophilization complexity and reducing manufacturing costs.

An intralumenal device uses an electrically-actuatable portion to disrupt the mucosal barrier for enhanced drug transfer.

A 70 bp SAR-BRI sequence from interferon alpha-2 stabilizes recombinant protein expression in mammalian cells.

Disrupting the KEX1 gene in yeast preserves C-terminal glycine integrity, enabling efficient conversion to biologically active alpha-amidated peptides.

Targeted amino acid substitutions in hAM15-52 analogues improve amylin receptor potency and metabolic stability, reducing fibrillation tendency.

Segmented hepcidin peptides mimic natural hormone activity by binding ferroportin, reducing patient burden from phlebotomy.

Proline substitutions in amylin derivatives reduce fibrillation tendency while maintaining solubility in acidic solutions, extending pharmacokinetic profiles.

A DLHW tetrapeptide compound increases neuronal viability through specific amino acid sequences.

Adrenocorticotropic hormone administration reduces renal biomarkers and improves glomerular filtration rate to address underlying etiology.

Covalent PEG attachment to metastin peptides resolves the contradiction between pharmacokinetic stability and receptor binding affinity.

Engineered cyclic peptides with disulfide bonds stabilize spexin analogs to treat obesity by activating GalR2 and GalR3 receptors.

Amphipathic helical proteins bypass endosomal trapping to deliver cargo directly into the cytosol.

A CT-proADM biomarker enables rapid in-vitro diagnosis of cardiovascular diseases and cardiac insufficiency.

VIP fragments reverse aortic fibrosis to normalize blood pressure, resolving the contradiction where conventional agents fail to control systolic pressure.

Conjugating apelin peptides with fatty acids extends half-life, resolving rapid degradation while maintaining efficacy.

Engineered mimylin peptides maintain receptor activity while achieving stability across a wide pH range.

Modifying amino acid sequences of natriuretic polypeptides reduces hypotensive effects while maintaining therapeutic efficacy for cardiovascular diseases.

Transformed mammalian cells expressing the ST6Gal catalytic domain produce therapeutic proteins with optimized human-like sialylation patterns.

Optimized proprotein convertase cleavage sites in modified precursors increase mature inhibin yield while reducing activin contamination.

Beta-arrestin 1 inhibitors reduce plasma aldosterone concentrations, attenuating adverse cardiac remodeling and improving function.

Polyglutamic acid suppresses blood GIP concentration, resolving safety and effectiveness trade-offs in existing anti-obesity agents.

Benzocyanine compounds add sulfonic acid substituents and polyethylene glycol chains to prevent aqueous aggregation, improving signal-to-noise ratios.

Fluorocarbon conjugates extend plasma half-life of peptides by resisting enzymatic degradation while maintaining GPCR binding affinity.

PEGylated polymeric nanoparticles extend drug half-life by reducing reticuloendothelial clearance, preserving articular cartilage in osteoarthritis.

Combining TRPV1 and TRPA1 agonists synergistically enhances adrenomedullin mRNA levels, overcoming the insufficient effects of single agonist therapies.

Conjugating hepcidin analogues with albumin extends in vivo half life while reducing aggregation for iron overload treatment.

Replacing labile peptide bonds with a disubstituted 1,2,3-triazole ring extends the half-life of KISS1R agonists while eliminating steroid persistence.

Tridentate ligands stabilize LHRH-metal complexes, resolving uncertain compound formation and safety concerns in reproductive cancer imaging.

A single-chain fusion protein uses a translocation domain to move protease into nociceptive sensory afferent cytosol.

Varying the proBNP to BNP-32 mole ratio in a reference standard set aligns corrected BNP concentrations from disparate assays, reducing deviation.

Fndc5 fragments activate PGC1α to drive brown fat thermogenesis, resolving the lack of specific molecular regulators for treating metabolic disorders.

Specific amino acid modifications in PYY compounds enhance Y2 receptor selectivity and prolong half-life to reduce dosing frequency.

Fluorocarbon-linked spexin analogs resolve metabolic instability and solubility trade-offs to deliver stable, non-immunogenic GALR2 agonists.

Amylin analogues delay gastric emptying and lower postprandial glucose levels, alleviating early satiety in patients with elevated glycemic excursion.

Modified apelin peptides resist proteolytic degradation by ACE2 and NEP enzymes, extending therapeutic duration for cardiovascular applications.

Chelating agents manage Cu(I) levels during 1,3-dipolar cycloadditions to prevent cellular damage while maintaining reaction efficiency.

Dual-target therapy inhibits pathological angiogenesis and reduces proliferative retinopathy side effects while improving visual acuity outcomes.

Lipidated PrRP analogs cross the blood-brain barrier via fatty acid chains to treat insulin resistance and chronic hyperglycemia.

Modifying the MIS protein cleavage site with a Kex sequence boosts production yield and resolves low cleavage efficiency bottlenecks.

A chimeric polypeptide induces antagonist antibodies against adrenomedullin receptors CLR, RAMP2, and RAMP3.

Biodegradable polymeric microparticles encapsulate timolol maleate to deliver the drug for up to 107 days, reducing systemic side effects and dosing frequency.

A peptide complex comprising Abeta 1-42 and undercarboxylated osteocalcin targets macrophages to regulate inflammatory responses.

Catestatin peptide promotes lipolysis by blocking alpha-adrenergic signaling, reversing leptin desensitization to treat obesity.